[Clinical Information] Patient initials or identifier number: 13069966 Relevant clinical history and physical exam: After fetal diagnosis of transposition of great arteries with restrictive atrial communication, the patient was delivered in the 38th week and performed balloon atrial septostomy immediately after birth. However, the patient was complicated with persistent pulmonary hypertension (PPHN) and presented with severe cyanosis. Extracorporeal membrane oxygenation had been needed for two weeks to get rid of PPHN. An arterial switch operation (ASO) was performed sixteen days after birth, while pleural effusion persisted after ASO. On the thirty-sixth days of his life, severe chylothorax and metabolic acidosis were suddenly appeared with severe edema in the head, neck and upper limbs, which suggested acute SVC obstruction. Relevant test results prior to catheterization: Central venous pressure was 26mmHg. Blood gas analysis revealed severe metabolic acidosis.
as alternatives to thrombus aspiration catheters. Final venography showed no residual stenosis. Fifty-sixth days after the procedure, venography revealed sufficient patency of SVC. SVC obstruction in early infancy is difficult to maintain patency and require frequent interventions. The Combination of PTA and transcatheter thrombectomy using sheath introducer may be feasible choice immediately after the obstruction of SVC.
Case Summary:
We report successful transcatheter aspiration of thrombus combined with percutaneous transluminal angioplasty (PTA) for an infant complicated by superior vena cava (SVC) obstruction in postoperative period presenting critical SVC syndrome. After fetal diagnosis of transposition of great arteries with restrictive atrial communication, the paitent was delivered in the 38th week and performed balloon atrial septostomy immediately after birth. However, the patient was complicated with persistent pulmonary hypertension (PPHN) and presented with severe cyanosis. Extracorporeal membrane oxygenation had been needed for two weeks to get rid of PPHN. An arterial switch operation (ASO) was performed sixteen days after birth, while pleural effusion persisted after ASO. Severe chylothrax was emerged on the thirty-sixth days of his life, while central venous pressure was elevated acutely followed by severe edema in the head, neck and upper limbs, which suggested SVC obstruction. After confirming the complete occlusion of SVC by venography, a Radifocus Ò guide wire was passed through the site of occlusion, over which PTA was performed. After PTA, venography showed residual stenosis and thrombus on the vessel wall. We advanced the sheath introducer from right juggler vein to the stenotic site and aspirated thrombus using the sheath. After removing a lot of thrombi, final venography showed no residual stenosis and thrombi. Fifty-six days after thrombectomy, venography revealed sufficient patency of SVC. SVC obstruction in early infancy may be difficult to maintain patency and require frequent interventions. Combination of PTA and transcatheter thrombectomy may be feasible choice immediately after the obstruction of SVC. He was born at gestational age35wks in birth weight 2.0kg as NSVD. Echocardiographic examination was done due to audible cardiac murmur and desaturation, which revealed pulmonary atresia with VSD, and short MPA segment and confluency of branch pulmonary arteries. At 24 HD, he received conduit insertion between right ventricle and pulmonary artery.
Relevant test results prior to catheterization:
On the cardiac CT taken at POD 6th, showed total occlusion at proximal LPA.
Relevant catheterization findings:
Right ventriculogram showed complete obstruction at proximal LPA suggesting ductal constriction.
[Interventional Management] Procedural step:
We passed the occluded segment with Grandslam Ashahi 0.014'' guide wire, and then did staged balloon angioplasty with 1.2mm and 2.5mm coronary balloon. Finally we put the 4mm*12mm stent at the occluded segment successfully.
TCTAP C-130
Stepwise Therapy for Severe Coarctation, PDA and Large VSD with Severe PAH Worakan Promphan Queen Sirikit National Institute of Child Health, Thailand
[Clinical Information] Patient initials or identifier number:
A 19 years old lady has moderate PDA, large inlet VSD and severe juxta-ductal COAT. She has been diagnosed as valvular heart disease at provincial hospital when she was 1 year of age. However, she lost to follow up since then and came back to the hospital with history of fatigue and hoarseness. Relevant clinical history and physical exam: Physical examination showed SpO2 of 85% in upper extremities. There was a systolic pressure difference of 10 mmHg between right arm and right leg. Her precordial was very active with grade 2/6 systolic murmur at left lower sternal border and grade 2/6 diastolic blowing murmur at left upper sternal border.
Relevant test results prior to catheterization:
The chest X-ray showed CT-ratio of 0.7 with a huge main pulmonary trunk. ECG demonstrated right axis deviation, presence of rsR' in V1, ST depression in right precordial leads. CT-angiogram showed inlet-perimembranous VSD 24 mm with bidirectional flow, PDA 12 mm with bidirectional flow, severe juxta-ductal COAT and very huge MPA compressed left main bronchus. Echocardiographic findings were similar to CTA and also confirmed a systemic pulmonary arterial pressure with severe right ventricular hypertrophy. Severe PAH in this patient may contributes from 3 major factors: large VSD /PDA, severe left sided obstruction, and high PVR. We decided first to put covered selfexpandable stent (Advanta V12 Atrium stent 16x61) and post-dilate with Z-Med balloon 23x30 mm to minimize DAO obstruction and PDA flow. Then, started oral sildenafil (or other pulmonary vasodilators) for at least 6 months and repeat flow/ resistance assessment again to assess feasibility of VSD closure. Case Summary: VSD, severe coarctation of the aorta and PDA with severe PAH. Successful covered stent placement at COAT. VSD will reassess the feasibility for closure in 6 months after oral sildenafil treatment as a priming pulmonary vasodilator. 
